INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral ...
A randomized clinical trial published in the Journal of Cannabis Research found that a traditional Thai cannabis-based multi-herbal formulation was just as effective as lorazepam in improving sleep ...
Patients taking CagriSema lost 23% of their body weight under the efficacy analysis, compared with 25.5% for tirzepatide ...
Novo Nordisk's next-gen obesity drug CagriSema failed to match Eli Lilly's Zepbound in a head-to-head trial, sending shares ...
Danish drugmaker Novo Nordisk (NOV: N) saw its shares sink more than 16% Monday after its obesity hopeful CagriSema (cagrilintide/semaglutide) failed to show non-inferiority to Eli Lilly’s (NYSE: LLY) ...
Novo Nordisk stock fell over 16% Monday after it said its next-generation weight loss drug didn't meet its primary target.
Press Release Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting ...
Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The ...
Viking Therapeutics Inc. (NASDAQ: VKTX) shares are up on Monday, in reaction to data from Novo Nordisk A/S’ (NYSE: NVO) ...
Novo Nordisk AS NVO, once the darling of the pharmaceutical world, tumbled Monday as investors reacted to what analysts are calling a “worst-case scenario.” NVO stock is tumbling. See the chart and ...
Eli Lilly shares climb after Novo Nordisk trial miss. CagriSema trails tirzepatide in 84-week weight-loss study results.
Novo Nordisk (NVO) stock drops 15% after CagriSema fails to match Eli Lilly's tirzepatide in an 84-week trial, hitting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results